ReviewAdvanced drug delivery reviews2007
Biodegradable nanoparticles for cytosolic delivery of therapeutics.
Review in Advanced drug delivery reviews, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
144 citing papers in PubMed, 528 citations in OpenAlex.
- Highly efficient and long-acting split-and-mix proteolysis targeting chimera based on self-assembled polylactic acid.Nature communications · 2025Article
- Aptamer-Coated PLGA Nanoparticles Selectively Internalize into Epithelial Ovarian Cancer Cells In Vitro and In Vivo.Biomolecules · 2025Article
- Revolutionizing Cancer Treatment: Harnessing the Power of Mesenchymal Stem Cells for Precise Targeted Therapy in the Tumor Microenvironment.Current topics in medicinal chemistry · 2025Review
- A Spotlight on PLGA-based Nanoparticles: Pioneering a New Era in the Therapeutics of Cardiovascular Disorders.Current pharmaceutical design · 2025Review
- Squalene in Nanoparticles Improves Antiproliferative Effect on Human Colon Carcinoma Cells Through Apoptosis by Disturbances in Redox Balance.International journal of molecular sciences · 2024Article
- PLGA-PEI nanoparticle covered with poly(I:C) for personalised cancer immunotherapy.Drug delivery and translational research · 2024Article
- From Polymeric Nanoformulations to Polyphenols-Strategies for Enhancing the Efficacy and Drug Delivery of Gentamicin.Antibiotics (Basel, Switzerland) · 2024Review
- Rejuvenating aged microglia by p16Molecular neurodegeneration · 2024Article
- Membrane-Cloaked Nanoparticles for RNA Interference of β-Catenin in Triple-Negative Breast Cancer.ACS biomaterials science & engineering · 2024Article
- Development of high-efficiency superparamagnetic drug delivery system with MPI imaging capability.Frontiers in bioengineering and biotechnology · 2024Article
- Nanospheres as the delivery vehicle: novel application ofFrontiers in immunology · 2024Article
- Mineralized Collagen/Polylactic Acid Composite Scaffolds for Load-Bearing Bone Regeneration in a Developmental Model.Polymers · 2023Article
- Imiquimod-Loaded Chitosan-Decorated Di-Block and Tri-Block Polymeric Nanoparticles Loaded In Situ Gel for the Management of Cervical Cancer.Gels (Basel, Switzerland) · 2023Article
- Review
- Red blood cell extracellular vesicles deliver therapeutic siRNAs to skeletal muscles for treatment of cancer cachexia.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Use of acidic nanoparticles to rescue macrophage lysosomal dysfunction in atherosclerosis.Autophagy · 2023Article
- PLGA Particles in Immunotherapy.Pharmaceutics · 2023Review
- Use of stimulatory responsive soft nanoparticles for intracellular drug delivery.Nano research · 2023Review
- 3D printing of polylactic acid: recent advances and opportunities.The International journal, advanced manufacturing technology · 2023Review
- Cytokine Therapy Combined with Nanomaterials Participates in Cancer Immunotherapy.Pharmaceutics · 2022Review
84 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Many therapeutics require efficient cytosolic delivery either because the receptors for those drugs are located in the cytosol or their site of action is an intracellular organelle that requires transport through the cytosolic compartment. To achieve efficient cytosolic delivery of therapeutics, different nanomaterials have been developed that consider the diverse physicochemical nature of therapeutics (macromolecule to small molecule; water soluble to water insoluble) and various membrane associated and intracellular barriers that these systems need to overcome to efficiently deliver and retain therapeutics in the cytoplasmic compartment. Our interest is in investigating PLGA and PLA-based nanoparticles for intracellular delivery of drugs and genes. The present review discusses the various aspects of our studies and emphasizes the need for understanding of the molecular mechanisms of intracellular trafficking of nanoparticles in order to develop an efficient cytosolic delivery system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.